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Yersinia pestis initiates infection as a facultative intracellular parasite in host macrophages; however, little
is known about the efficacy of antibiotics commonly used to treat human plague against intracellular Y. pestis.
Intracellular minimal bactericidal concentrations (MBCs) were determined using a high-throughput broth
microdilution assay in which human THP-1 macrophage-like cells were infected with Y. pestis strain KIM6-
2053.1 and exposed to 2-fold serial dilutions of antibiotics for 24 h in 96-well plates. The numbers of CFU,
upon which minimal bactericidal concentrations were based, were determined by counting “microcolonies” in
wells of 96-well plates following lysis of tissue culture cells to release surviving Y. pestis, replica dilution, and
plating in soft tryptic soy broth agar. For THP-1 cells, streptomycin and ciprofloxacin had comparable
efficacies for intra- and extracellular Y. pestis, but the MBCs for chloramphenicol, gentamicin, doxycycline, and
amoxicillin were two-, three-, four-, and five 2-fold serial dilutions greater, respectively, for intracellular than
for extracellular Y. pestis. During the initial stage of plague, intracellular Y. pestis may be less susceptible to
antibiotic killing by particular antibiotics recommended for treatment of plague, such as gentamicin or
doxycycline, whereas others, such as streptomycin and ciprofloxacin, may have similar efficacies against
extracellular or intracellular Y. pestis. This may be of particular importance in the selection of antibiotics for
prophylactic treatment in the case of a bioterrorism event.
Yersinia pestis, a facultative intracellular Gram-negative bac-
terium, causes vector-transmitted plague epizootics in defini-
tive rodent hosts and sporadic cases in dead-end hosts such as
humans (22, 27). In humans, three common clinical presenta-
tions for plague are bubonic, septicemic, and pneumonic, with
bubonic being the most prevalent and least severe form and
pneumonic the least prevalent and most severe of naturally
transmitted plague. Unnatural transmission by bioterrorism is
anticipated to result in virtually 100% primary pneumonic
plague (3, 13, 19). Case fatality rates for bubonic and septice-
mic plague can be as high as 40%, underlying the potential for
the difficulty of successful treatment of plague with antibiotic
therapy (10, 17), whereas case fatality rates for pneumonic
plague can be 100% if not treated within 24 h of onset of
clinical symptoms. Although most strains of Y. pestis are sen-
sitive to commercially available antibiotics in vitro, treatment
failures occur (4, 12). These failures are attributed typically to
delayed diagnosis, untimely initiation of treatment, or use of
inappropriate antibiotics (4, 7, 11). However, another potential
cause is the failure of antibiotics to kill intracellular Y. pestis (1,
13). During the initial 36-to-72-h phase of infection, Y. pestis
invades host macrophages to escape innate immunity (25), and
this intracellular Y. pestis may be less sensitive to antibiotic
killing (1; J. D. Wendte, D. Ponnusamy, and K. D. Clinken-
beard, presented at the 6th ASM Biodefense and Emerging
Diseases Research Meeting, Baltimore, MD, 2008). Prophy-
lactic antibiotic treatment for a mass casualty bioterrorism
event may benefit from antibiotics that are efficacious against
intracellular Y. pestis.
Streptomycin, introduced in 1944, continues to be recom-
mended as the first-line treatment of human plague (3, 18),
although issues with resistance, the requirement for injectable
rather than oral delivery, and limited product availability sug-
gest that newer and more readily available antibiotics might be
better choices for treatment of plague. In addition to strepto-
mycin, other antibiotics recommended for treatment of plague
are gentamicin, doxycycline, and ciprofloxacin; however, there
are limited studies upon which to base these recommendations
(4, 23, 26).
We developed a high-throughput (HTP) assay to study an-
tibiotic efficacy against intracellular Y. pestis (J. D. Wendte et
al., presented at the 6th ASM Biodefense and Emerging Dis-
eases Research Meeting, Baltimore, MD, 2008), with the aim
of providing additional data for the rational use of antibiotics
for treatment of plague, particularly those with efficacy against
intracellular Y. pestis. We found that two of four antibiotics
recommended for treatment of plague, gentamicin and doxy-
cycline, were markedly less efficacious against intracellular Y.
pestis in vitro, whereas ciprofloxacin and streptomycin had ac-
tivity against intracellular Y. pestis similar to or better than that
against extracellular Y. pestis (J. D. Wendte et al., presented at
the 6th ASM Biodefense and Emerging Diseases Research
Meeting, Baltimore, MD, 2008). The Working Group on
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Civilian Biodefense recommends doxycycline for the mass-ca-
sualty setting and postexposure prophylaxis, with ciprofloxacin as
an alternative (18), but doxycycline does not appear to be as
effective against intracellular Y. pestis, the form of the bacteria
which may be most prevalent during prophylaxis, whereas cipro-
floxacin and streptomycin have similar levels of activity against
both extracellular and intracellular Y. pestis in vitro.
MATERIALS AND METHODS
Bacterial strains. Y. pestis strain KIM6-2053.1 hms psn Psa (psa2053.1)
Ybt Lcr derived from KIM6-2053.1 (2) and provided by Robert Perry, Uni-
versity of Kentucky, was transformed with a modified green fluorescent protein
expression plasmid (pGFPuv; Clontech) by electroporation (9). Plasmid pGFPuv
was modified by BsaH1 (New England BioLabs) restriction excision of a portion
of the Ampr selection marker between bp 1402 and 1784 of pGFPuv, and
religation followed. Electroporation-transformed bacteria were grown on tryptic
soy agar (TSA; Difco), and transformants expressing uvGFP were identified
visually using a 360-nm illumination box (VersaDoc; Bio-Rad). A transformant
which stably expressed uvGFP was selected (KIM6-2053.1GFPuv). Growth of
KIM6-2053.1GFPuv in liquid media and in tissue culture cells was indistin-
guishable from that of the parent KIM6-2053.1 strain (data not shown).
Tissue culture cells. Human THP-1 and mouse RAW264.7 cells (American
Type Tissue Culture Collection) were cultured at 37°C in 5% CO2 in RMPI 1640
media (Sigma-Aldrich) supplemented with 10% fetal bovine serum (FBS; Hy-
Clone), 10 mM HEPES (Sigma-Aldrich), 1 mM sodium pyruvate (Sigma-Al-
drich), 4.5 g/liter glucose (Sigma-Aldrich), and 1.5 g/liter sodium bicarbonate
(Sigma-Aldrich), with pH adjusted to 7.2, with the exception that media for
THP-1 cells also contained 50 M 2-mercaptoethanol (Sigma-Aldrich).
Infection of tissue culture cells. Prior to use in assays, tissue culture cell
viability was assessed by a trypan blue exclusion assay, with 95% viability
required for subsequent use. To prepare RAW264.7 cells for infection as at-
tached cells, 5 ml (1  106 cells/ml quantified by hemocytometer) RAW264.7
cells was placed in 25-cm2 tissue culture flasks incubated overnight at 37°C with
5%CO2. THP-1 cells were infected as suspension cultures. For infection of tissue
culture cells, Y. pestis strain KIM6-2053.1 pGFPuv was grown in brain heart
infusion (BHI) broth (Difco) at 26°C in an incubator shaker at 120 rpm, and the
inocula were quantified at an optical density at 600 nm (OD600) against a
standard curve for the number of CFU/OD600. Sufficient inoculum was added to
the tissue culture flasks to yield an optimal multiplicity of infection (MOI) of 4:1
for RAW264.7 cells and 6:1 for THP-1 cells, as determined for the infection
conditions utilized. Flasks containing RAW264.7 cells were centrifuged at 150 
g for 10 min to facilitate bacterial contact with RAW264.7 cells, but THP-1 cell
suspensions were mixed with inocula and not centrifuged. The flasks were then
incubated for 30 min at 37°C with 5% CO2, prior to clearing extracellular
bacteria by addition of 50 g/ml gentamicin to flasks, and the incubation de-
scribed above continued for an additional 2 h. For flasks containing RAW264.7
cells, the gentamicin-containing medium was removed by aspiration, and the
flasks were washed twice with phosphate-buffered saline (PBS) to remove resid-
ual gentamicin. Subsequently, RPMI 1640 medium containing no antibiotic was
added to flasks, and RAW264.7 cells were detached from the flasks using a cell
scraper. For THP-1 cells, following 2-h exposure to gentamicin, cells were col-
lected by centrifugation at 200  g for 6 min, gentamicin-containing medium was
removed by aspiration, and the cell pellet was washed twice with PBS prior to
resuspending the cells in RPMI 1640 medium containing no antibiotics. Y. pestis
cells were located primarily intracellularly in infected tissue culture cells postin-
fection as shown in Fig. 1.
Antibiotics. Ciprofloxacin (Serologicals), streptomycin, gentamicin, doxycy-
cline, and amoxicillin (all from Sigma-Aldrich) stock solutions made in sterile
water were stored at 80°C and used within 3 weeks of preparation. Chloram-
phenicol (Sigma-Aldrich) stock solution was made in dimethyl sulfoxide
(DMSO) and used the same day due to concerns with stability.
BMA. Broth microdilution assays (BMA) for both intracellular and extracel-
lular Y. pestis were conducted in single 96-well plates with two antibiotics tested
per plate. Gentamicin was used as a standard antibiotic for efficacy assessment
and was included in all BMA plates. To prepare 96-well flat-bottom plates
(Corning) for BMA, 80 l of 2-fold serially diluted test antibiotics in RPMI 1640
medium supplemented with 10% FBS were added to all wells in the top seven
rows (A through G) of plates, yielding serial 2-fold dilutions in a series down
each column of a plate. The wells in the eighth row (H) of each column were
reserved and served as either growth control wells receiving 80 l of RPMI 1640
media with 10% FBS and no antibiotic or sterility control wells that contained 80
l of the highest antibiotic concentration in the dilution series in RPMI 1640
medium with 10% FBS, but these sterility control wells were not subsequently
inoculated with Y. pestis such that the antibiotics could be assessed for contam-
ination. Each plate contained one standard antibiotic (gentamicin) and one test
antibiotic, with each antibiotic series dilution repeated in 6 of the 12 columns of
the plate. Plates were stored at 20°C until used. To assess antibiotic efficacy
against intracellular Y. pestis, 20 l containing 5  104 CFU Y. pestis in 1  105
tissue culture cells was added to the top seven rows (A through G) of three of the
six columns for each test antibiotic and to the nonantibiotic-containing growth
control wells in the eighth (H) row. In the remaining three columns for each
antibiotic, 20 l of a 1:40 dilution in PBS of a 0.5 McFarland standard suspension
Y. pestis (5  104 CFU Y. pestis/well) prepared from bacteria grown on BHI agar
(Difco) at 37°C was added to assess antibiotic efficacy against extracellular Y.
pestis and to serve as comparators for antibiotic efficacy against intracellular Y.
pestis. Immediately following inoculation of plates, aliquots were taken from two
growth control wells per plate for infected tissue culture cells to determine the
initial number of CFU/wells. These aliquots containing infected cells were
treated with 0.1% Triton X-100 (Sigma-Aldrich) in PBS to lyse cells releasing
intracellular bacteria for CFU enumeration by the plating of serial dilutions on
10-cm TSA agar petri dishes. The acceptable inoculum for CFU per well was
5  104 CFU/well (5  105 CFU/ml).
Antibiotic exposure was continued for 24 h at 37°C with 5% CO2, and the
minimal bactericidal concentration (MBC) determined from the number of CFU
in wells by a novel HTP microcolony assay in replicate 96-well plates by modi-
fication of a method of Nizet and colleagues (21). Briefly, 100 l sterile water was
added to wells in those plate columns that contained the extracellular bacterial
inocula, and 100 l 0.1% Triton X-100 in serial water was added to wells in those
plate columns that contained infected tissue culture cells as inocula. Plates were
then placed on a rotary shaker for 10 min to allow the lysis of tissue culture cells
and resuspension of bacteria in wells. Bacteria in wells were then diluted 10-fold
by the transfer of 20 l of well contents to a replica 96-well dilution plate
containing 180 l sterile water in all wells. Finally, following mixing, 20 l of well
contents in the replica 96-well dilution plate were transferred to a replica 96-well
CFU plate, and 180 l of tryptic soy broth in 0.5% Bacto-agar (Difco) main-
tained at 45°C was added to all wells. The CFU plates were incubated for 16 h
at 37°C. CFU were quantified by visual counting of microcolonies in individual
wells using a dissecting microscope (Fig. 2).
MBCs, defined as a 99.9% reduction in the initial inoculum, were determined
from the number of CFU/well compared to the growth controls. The minimum
inoculum per well was 5  104 CFU/well in the exposure plate, which following
dilution would be 5  102 CFU per well in the CFU plate. Therefore, a 99.9%
reduction would be 0.5 CFU/well or no growth observed in wells at the MBC
antibiotic concentration in the CFU plate. For MBC determinations, the number
of CFU/well was estimated visually by categorization of wells as 0, 1 to 20, 20 to
100, 100 to 1,000, or 1,000 microcolonies per well (Fig. 2). The MBC was the
lowest antibiotic concentration with 0 CFU/well. For the MBC to be valid, those
wells with lower concentrations of antibiotics than the MBC must have had 20
CFU per well, with no skipped wells. The antibiotic concentration ranges for
each test antibiotic were selected by initial testing such that ranges included at
least one dilution above and below the low and high MBCs observed.
RESULTS
Antibiotics commonly used for treatment of plague were
assessed for in vitro efficacy against intracellular Y. pestis by
FIG. 1. At 4 h postinfection, Y. pestis was located primarily intra-
cellularly in human THP-1 cells (A) and mouse RAW264.7 cells
(B) (magnification, 1,500).
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comparison of the MBCs for antibiotics against intracellular
bacteria in macrophage cell lines compared to extracellular
bacteria using a novel 96-well plate-based method for enumer-
ation of CFU developed by Nizet and colleagues (21). This
novel 96-well plate method requires fewer manipulations than
the standard serial dilution method for determination of the
number of CFU using 10-cm petri dishes and made it feasible
to determine the number of CFU over an extended range of
2-fold serial dilutions of antibiotic concentrations, with greater
numbers of replicates per antibiotics for the determination of
the MBCs of commercially available antibiotics for intracellu-
lar Y. pestis (21; J. D. Wendte et al., presented at the 6th ASM
Biodefense and Emerging Diseases Research Meeting, Balti-
more, MD, 2008).
This HTP BMA format allowed three replicates of seven
2-fold serial dilutions of a test antibiotic and a standard anti-
biotic to be assessed against both intracellular and extracellular
Y. pestis in a single 96-well plate, reducing the material re-
quired and easing the manipulations required for MBC deter-
minations. For this HTP BMA, Y. pestis-infected tissue culture
macrophage-like cells (5  104 CFU Y. pestis per 1  105
macrophages/100 l per well) were subjected to antibiotic ex-
posure in 96-well plates for 24 h at 37°C. At the end of the
antibiotic exposure, Y. pestis was released from macrophages
by detergent lysis and diluted in a replica 96-well dilution plate,
and finally, the number of CFU was determined by visual
microscopic examination of microcolonies following 100-fold
dilution and growth in soft TSA in a final 96-well CFU plate.
The validity of the microcolony assessment of the number of
CFU was confirmed by comparison plating on 10-cm TSA petri
dishes with the number of CFU determined by the soft TSA
microcolony method in 96-well plates as shown in Fig. 3. There
was a 0.5 to 1.0 correspondence of CFU for Y. pestis strain
KIM6-2053.1GFPuv enumerated by serial dilution and plat-
ing on 10-cm TSA petri dishes or inoculation of soft TSA in
96-well plates across three experiments (n  4 to 8).
Using the HTP BMA, MBCs for five antibiotics (streptomy-
cin, gentamicin, doxycycline, chloramphenicol, and ciprofloxa-
cin) commonly used to treat plague in humans and amoxicillin
(included as a test antibiotic with anticipated poor intracellular
efficacy) were determined for intracellular Y. pestis KIM6-
2053.1GFPuv in THP-1 human tissue culture macrophage
cell lines and for extracellular Y. pestis. THP-1 cells were un-
differentiated and monocyte-like in suspension culture and are
phagocytic but have limited antimicrobial activity (24). As
shown in Table 1, MBCs for extracellular Y. pestis for genta-
micin, doxycycline, and ciprofloxacin were 100% within the
Clinical and Laboratory Standards Institute ranges for the ex-
pected MIC, whereas 73% and 88% of MBCs for chloram-
phenicol and streptomycin were within this expected range for
MICs (8).
Comparisons of MBCs for intracellular and extracellular Y.
pestis in Table 1 show that for THP-1 cells MBCs for strepto-
mycin were the same or one 2-fold dilution lower for intracel-
lular versus extracellular Y. pestis, whereas MBCs for intracel-
lular versus extracellular Y. pestis were one 2-fold dilution
higher for ciprofloxacin, two 2-fold dilutions higher for chlor-
amphenicol, three 2-fold dilutions higher for gentamicin, four
2-fold dilutions higher for doxycycline, and five 2-fold dilutions
higher for amoxicillin.
MBCs were also determined for intracellular Y. pestis in
mouse RAW264.7 macrophage-like cells. RAW264.7 cells
used were not activated by pretreatment and were adherent,
phagocytic cells with some antimicrobial activity (20). The
MBCs were the same for mouse RAW264.7 and human THP-1
macrophage-like cells for streptomycin, chloramphenicol, cip-
rofloxacin, and amoxicillin but were two to three 2-fold dilu-
tions lower for RAW264.7 than for THP-1 cells for gentamicin
and doxycycline. Microscopic examination of Y. pestis KIM-
FIG. 2. Visual comparison of microcolonies in wells of 96-well
plates (A1 to A4; magnification, 15) with colonies on 10-cm petri
dish for CFU determinations (B1 to B4). Representative examples are
shown of single wells for MBC determinations yielding results that
were within the four scoring categories used for MBC determinations.
The numbers of CFU/plate well or 10-cm petri dish are shown on left.
FIG. 3. Comparison of CFU determinations for Y. pestis using mi-
crocolony visualization with wells of 96-well plates and for colonies on
standard 10-cm petri dishes. Identical samples of Y. pestis were inoc-
ulated in wells of 96-well plates and mixed with TSA soft agar or
streaked on 10-cm TSA petri dishes as described in Materials and
Methods. Statistical analysis using a simple linear regression (R 
0.979) suggests that these techniques yield similar results within one-
order-of-magnitude agreement.
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2053.1GFPuv demonstrated that the bacteria were located
intracellularly in the tissue culture cells (Fig. 1) and that in
human THP-1 cells the bacteria were present in tight vesicles
in the cytoplasm, whereas in mouse RAW264.7 cells the bac-
teria were in spacious cytoplasmic vesicles (Fig. 4).
DISCUSSION
Commonly used methods for in vitro antibiotic sensitivity
testing for intracellular bacteria involves CFU determination
by plating serially diluted samples on 10-cm petri dishes, which
is a labor-intensive process with limited potential for HTP
development. Because of this, the range of antibiotic serial
dilutions that can be accomplished in individual assays, as well
as the number of replicates of individual MBCs that can be
accomplished, is often limited. Alternative methods have been
developed that use determinants other than the number of
CFU to assess antibiotic efficacy in the HTP format (5, 28), but
we report herein an adaptation of a novel method for CFU
determination for intracellular bacteria in a 96-well-plate for-
mat previously developed by Nizet and colleagues (21) for an
HTP BMA for intracellular Y. pestis which uses the more
traditional CFU determination for assessing antibiotic efficacy.
This method allows screening of seven 2-fold antibiotic dilu-
tions to yield 12 MBC determinations per 96-well plate. In
addition, the determinations of MBCs for both intracellular
and extracellular bacteria can be conducted in the same plate.
Although not done for the MBC determinations reported in
this study, this method is amenable to the use of robotics to
further reduce the labor required for testing.
To our knowledge, information on in vitro antibiotic sensi-
tivity testing for intracellular Y. pestis is not currently available
in the literature. The necessity of such information has recently
become apparent with the appreciation that during the initial
phase in plague, Y. pestis resides in host macrophages in which
it suppresses immune responsiveness and evades innate immu-
nity (25). Therefore, antibiotics which act effectively against
both intracellular and extracellular Y. pestis may have the best
potential for efficacy. Recommendations for antibiotics for
treatment of human plague are based on limited clinical trials
and experimental infections in rodents. Of particular recent
interest are recommendations for prophylactic antibiotic ther-
apy in a bioterrorism incident involving Y. pestis. Because Y.
pestis uses intracellular parasitism of host macrophages as one
mechanism of evasion of host innate immunity during the
initial phase of infection, it is reasonable to conclude that
antibiotics effective against intracellular Y. pestis might be su-
TABLE 1. Comparison of MBC determinations for extracellular and intracellular Y. pestis
Antibiotic BMA typea
No. of assay determinations with an MBC (g/ml) of: Total no. of
assaysb0.016 0.03 0.06 0.13 0.25 0.5 1 2 4 8 16 32 64 128
Streptomycin EC 8 37 16 8 69
THP-1 17 13 5 1 36
RAW 14 17 8 39
Gentamicin EC 34 91 38 10 173
THP-1 3 1 9 27 30 11 81
RAW 11 28 33 25 4 1 102
Doxycycline EC 1 11 62 11 85
THP-1 11 20 8 39
RAW 3 2 10 13 7 3 38
Chloramphenicol EC 2 33 7 6 48
THP-1 7 16 15 38
RAW 5 4 12 13 34
Ciprofloxacin EC 16 52 68
THP-1 5 14 8 5 7 39
RAW 7 17 13 2 39
Amoxicillin EC 5 15 6 4 30
THP-1 1 17 7 25
RAW 1 3 5 14 1 24
a Broth microdilution assay type specifies whether Y. pestis was exposed to antibiotics extracellularly (EC), intracellularly in the THP-1 human macrophage cell line
(THP-1), or in the RAW264.7 mouse macrophage cell line (RAW).
b The plate assay setup resulted in twice as many EC assays as assays for either THP-1 or RAW. Some MBCs were rejected if the inoculum was determined to not
be within the range of 5  104 to 5  105 CFU Y. pestis/well.
FIG. 4. At 12.5 h postinfection, Y. pestis resides in tight cytoplasmic
vesicles in human THP-1 cells (A) but in spacious cytoplasmic vesicles
in mouse RAW264.7 cells (B) (magnification, 1,500, Wright-Giemsa
stain).
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perior as prophylaxis for acute exposure to plague. Using the
HTP BMA described, we determined that two recommended
antibiotics, streptomycin and ciprofloxacin, had superior effi-
cacy against intracellular Y. pestis in human macrophage-like
cells, whereas two other recommended antibiotics, gentamicin
and doxycycline, had inferior efficacy.
Compared to an abundance of information available on the
antibiotic sensitivity of many common bacterial pathogens,
only limited information is available for Y. pestis. Acceptable
limits for antibiotic sensitivity for Y. pestis for in vitro sensitivity
testing are available for only six commercial antibiotics (8).
Good antibiotic sensitivity was observed with in vitro sensitivity
testing conducted on several clinical isolate collections, with
the exception that isolates collected more recently have in-
creased MICs (26). Y. pestis isolates collected prior to 1988 had
MICs 	8 g/ml for 23 of 24 commercially available antibiotics
(16). Similarly, a survey of 100 clinical isolates collected prior
to 1991 from Africa for 14 commercially available antibiotics
found that all were effective at 	8 g/ml except for one mac-
rolide antibiotic (12). For a collection of 78 Y. pestis isolates
from Vietnam from 1985 to 1993, all were susceptible to 14
commercial antibiotics at 8 g/ml; however, the authors noted
that the MICs for several antibiotics commonly used in Viet-
nam were less effective (26). The most recently screened col-
lection consisted of 92 isolates (not all are from human cases)
from California from 1977 to 1998, and 12 commercially avail-
able antibiotics were found to be effective at 8 g/ml (29).
The recommended antibiotic of choice for treatment of hu-
man plague is streptomycin (14), but with the emergence of
streptomycin-resistant strains and the limited availability of
streptomycin, reliance on this drug for the treatment of plague
has decreased (4, 15). Doxycycline, chloramphenicol, gentami-
cin, and ciprofloxacin are recommended for treatment of
plague and are more commonly used today (4, 14), although
inhibitory in vitro 
-lactams and sulfas may not be effective in
vivo (6).
As with any in vitro assay, the applicability of the results
reported for therapeutic decision-making depends on the abil-
ity of the in vitro-model THP-1 cells and target Y. pestis strain
KIM6-2053.1 to accurately reflect the circumstances in actual
in vivo infections. THP-1 cells are one of several macrophage-
like cell lines used to model intracellular parasitism. Several
other human macrophage- or monocyte-like cell lines, includ-
ing HL60 and A529, were assessed with various avirulent
strains of Y. pestis, with THP-1 cells exhibiting the most con-
sistent intracellular infectivity over a 24-h observation (data
not shown). Likewise, of the various avirulent Y. pestis strains
which are mutants for particular virulence loci, strain KIM6
lacking the plasmid pCD, strain D27 lacking the chromo-
somal pigment loci, and D1 lacking the MT plasmid, only
KIM6 yielded consistent intracellular parasitism of human
macrophage-like cells for 24 h (data not shown). Additional
studies are needed to determine how well THP-1 cells and
Y. pestis strain KIM6-2053.1 mimic the sensitivity of native
virulent strains of Y. pestis in human macrophages to various
antibiotics.
In addition to testing antibiotic efficacy against intracellular
Y. pestis in a human cell line, antibiotic efficacy against Y. pestis
in a mouse macrophage cell line, RAW264.7, was also assessed
and found to differ for two antibiotics, gentamicin and doxy-
cycline, with these antibiotics being more efficacious in mouse
than in human macrophage cell lines. Intracellular antibiotic
efficacy is dependent on several pharmacokinetic and pharma-
codynamic factors relating to the properties of both the host
macrophages and the agent in these host macrophages.
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